Compare Astena Holdings Co., Ltd. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
JPY 19,891 Million (Small Cap)
9.00
NA
0.21%
0.45
8.38%
0.73
Revenue and Profits:
Net Sales:
17,267 Million
(Quarterly Results - Nov 2025)
Net Profit:
551 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.82%
0%
8.82%
6 Months
-0.41%
0%
-0.41%
1 Year
-1.23%
0%
-1.23%
2 Years
5.25%
0%
5.25%
3 Years
11.09%
0%
11.09%
4 Years
-28.64%
0%
-28.64%
5 Years
0.63%
0%
0.63%
Astena Holdings Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.85%
EBIT Growth (5y)
12.39%
EBIT to Interest (avg)
21.22
Debt to EBITDA (avg)
1.74
Net Debt to Equity (avg)
0.43
Sales to Capital Employed (avg)
1.27
Tax Ratio
100.00%
Dividend Payout Ratio
33.19%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.25%
ROE (avg)
6.70%
Valuation key factors
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
0.77
EV to EBIT
8.88
EV to EBITDA
5.14
EV to Capital Employed
0.84
EV to Sales
0.51
PEG Ratio
NA
Dividend Yield
0.21%
ROCE (Latest)
9.45%
ROE (Latest)
8.66%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Nov'25 - QoQ
Nov'25
Aug'25
Change(%)
Net Sales
17,267.00
15,375.00
12.31%
Operating Profit (PBDIT) excl Other Income
215.00
581.00
-62.99%
Interest
56.00
47.00
19.15%
Exceptional Items
88.00
-48.00
283.33%
Consolidate Net Profit
551.00
347.00
58.79%
Operating Profit Margin (Excl OI)
12.50%
37.80%
-2.53%
USD in Million.
Net Sales
QoQ Growth in quarter ended Nov 2025 is 12.31% vs -2.49% in Aug 2025
Consolidated Net Profit
QoQ Growth in quarter ended Nov 2025 is 58.79% vs -55.51% in Aug 2025
Annual Results Snapshot (Consolidated) - Nov'25
Nov'25
Nov'24
Change(%)
Net Sales
62,744.00
57,993.40
8.19%
Operating Profit (PBDIT) excl Other Income
5,446.00
5,402.90
0.80%
Interest
220.00
88.60
148.31%
Exceptional Items
-178.00
-4,525.70
96.07%
Consolidate Net Profit
2,179.00
-2,538.00
185.86%
Operating Profit Margin (Excl OI)
48.10%
48.60%
-0.05%
USD in Million.
Net Sales
YoY Growth in year ended Nov 2025 is 8.19% vs 11.56% in Nov 2024
Consolidated Net Profit
YoY Growth in year ended Nov 2025 is 185.86% vs -320.06% in Nov 2024
About Astena Holdings Co., Ltd. 
Astena Holdings Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






